Results 81 to 90 of about 22,911 (183)
Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE ...
John P Mills +3 more
core +1 more source
METHOD DEVELOPMENT AND VALIDATION FOR MEROPENEMAND VABORBACTAM BY RP-HPLC METHOD
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in Tablet dosage form. Chromatogram was run through Inertsil ODS C185mm (4.6 x 250mm).
D.Vaishnavi, Dr V.Kiran Kumar
core +1 more source
Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide [PDF]
Abstract Background Meropenem-vaborbactam (MER-VAB) is a carbapenem-β-lactamase inhibitor combination with enhanced activity against KPC-producing Enterobacteriaceae recently evaluated in a phase 3 clinical trials for cUTIs and infections due to CRE.
Castanheira, Mariana +4 more
openaire +1 more source
Objectives This study investigated the prevalence of AmpC beta‐lactamase‐producing Escherichia coli and Klebsiella pneumoniae in clinical specimens collected in Lahore, Pakistan, and aimed to identify potential inhibitors targeting AmpC beta‐lactamases. Methods A total of 17,500 clinical specimens were collected from June 2018 to June 2021 and analyzed
Muhammad Sarfraz +10 more
wiley +1 more source
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang +5 more
wiley +1 more source
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in tablet dosage form. Chromatogram was run through SB C8 100 x 3.0 mm, 1.8m.
Sudha Rani Bollimuntha 1 *, Kalyana Seela Kottapalli 2, Bhavya Manda 3
core +1 more source
Herein, we report the in vivo evolution of imipenem/relebactam-resistance in KPC-producing K. pneumoniae (KPC-Kp) isolated from a critically-ill patient treated with multiple combination therapies based on ceftazidime-avibactam or meropenem-vaborbactam ...
Boattini, Matteo +5 more
core +1 more source
Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative <i>Klebsiella pneumoniae</i>. [PDF]
Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam.
Avison, Matthew B +7 more
core +1 more source
Relapsing Salmonella Meningitis in an Infant: A Case Report and Review of the Literature
Accurate diagnosis of bacterial meningitis is critical, particularly in young febrile infants. Although commercially available multiplex PCR assays enable rapid pathogen detection, these typically do not include Salmonella spp. or other Enterobacteriaceae, which may result in missed diagnoses and/or inappropriate treatment duration.
Sonia Alexiadou +7 more
wiley +1 more source
Vaborbactam (formerly RPX7009) is a new β-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against K lebsiella p neumoniae
Debora Rubio-Aparicio +4 more
core +1 more source

